



At Novo Nordisk, we understand that our medicines are important to patients. As part of our commitment to sharing timely and transparent information, we want to provide you with an important supply update about Norditropin®(somatropin) injection 5mg, 10mg, 15mg, and 30mg.

Novo Nordisk continues to experience supply constraints of Norditropin® due to lower than anticipated output in our production facility, exacerbated by additional unanticipated delays caused by longer lead times for production and batch release. However, the overall supply of Norditropin® is increasing across all pen strengths compared to the last few months with the availability of 10mg and 15mg pens improving the most. While we are releasing more Norditropin®, it might take a few weeks for it to move through the supply chain.

We continue to work hard to resolve the issues and we have taken steps to optimize our Norditropin® output. In addition to optimizing our current manufacturing lines, we are working to ensure a sustainable supply of our products by investing significant resources in building new plants and production lines.

For patients who are unable to fill their prescription, we recommend they speak with their healthcare provider to determine the best course of action. Healthcare providers know their patients' past and current medical history and are best equipped to make clinical recommendations.

Please know that we recognize that our supply challenges have been extremely difficult for patients and their caregivers and understand the frustration as the supply shortage has persisted longer than we anticipated. We remain steadfast in our commitment to serve this community and provide patients with the medications they have come to rely on.

Thank you for your patience. We will share updates quarterly as we move forward to keep you informed of our progress.

Sincerely,  
Novo Nordisk

Norditropin® is registered trademarks of Novo Nordisk Health Care AG.

Novo Nordisk is a registered trademark of Novo Nordisk A/S.

All other trademarks, registered or unregistered, are the property of their respective owners.

©2023 Novo Nordisk All rights reserved. US23REND00007 December 2023